MiMedx Group Inc
NASDAQ:MDXG
MiMedx Group Inc
Other Long-Term Assets
MiMedx Group Inc
Other Long-Term Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Long-Term Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
MiMedx Group Inc
NASDAQ:MDXG
|
Other Long-Term Assets
$31.8m
|
CAGR 3-Years
373%
|
CAGR 5-Years
129%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Other Long-Term Assets
$9.1B
|
CAGR 3-Years
30%
|
CAGR 5-Years
36%
|
CAGR 10-Years
20%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Other Long-Term Assets
$6.1B
|
CAGR 3-Years
7%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
16%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Other Long-Term Assets
$9.9B
|
CAGR 3-Years
15%
|
CAGR 5-Years
41%
|
CAGR 10-Years
20%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Other Long-Term Assets
$3.3B
|
CAGR 3-Years
50%
|
CAGR 5-Years
21%
|
CAGR 10-Years
101%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Other Long-Term Assets
$4.5B
|
CAGR 3-Years
61%
|
CAGR 5-Years
37%
|
CAGR 10-Years
32%
|
|
MiMedx Group Inc
Glance View
MiMedx Group Inc. is a fascinating player in the realm of life sciences, operating at the dynamic intersection of biotechnology and tissue engineering. Nestled in the healthcare sector, MiMedx specializes in developing and distributing regenerative biomaterials and allografts derived from human amniotic tissue. This niche focus allows the company to tap into the potential of natural biologics to promote effective healing and enhance patient outcomes, particularly in chronic and complex wound care. Their product offerings, which primarily include amniotic membrane and umbilical cord products, are harnessed to aid in tissue repair and to reduce inflammation and scarring, all of which are critical elements in successful clinical treatment. In terms of revenue generation, MiMedx's business model revolves around an intricate balance of innovation and strategic partnerships. By meticulously refining their proprietary processing techniques, the company maintains a competitive advantage that appeals to healthcare providers across various specialties, including orthopedics, podiatry, and reconstructive surgery. Revenue streams are predominantly driven by the sale of these biotechnology innovations to hospitals, healthcare providers, and through direct distribution channels. Further enhancing their financial robustness, MiMedx invests in extensive clinical trials and research, which underpin their marketing and educational efforts to broaden the adoption of their products. With a keen eye on developing medical solutions that cater to an aging population and a growing demand for effective wound care products, MiMedx positions itself as a crucial innovator in its sector.
See Also
What is MiMedx Group Inc's Other Long-Term Assets?
Other Long-Term Assets
31.8m
USD
Based on the financial report for Sep 30, 2024, MiMedx Group Inc's Other Long-Term Assets amounts to 31.8m USD.
What is MiMedx Group Inc's Other Long-Term Assets growth rate?
Other Long-Term Assets CAGR 5Y
129%
Over the last year, the Other Long-Term Assets growth was 31 716%. The average annual Other Long-Term Assets growth rates for MiMedx Group Inc have been 373% over the past three years , 129% over the past five years .
You don't have any saved screeners yet